Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N (2021) Cancer Therapy-Associated Thromb Arterioscler Thromb Vascular Biology 41(4):1291–1305

Article  CAS  Google Scholar 

Khorana AA, Kuderer NM, McCrae K, Milentijevic D, Germain G, Laliberté F, MacKnight SD, Lefebvre P, Lyman GH, Streiff MB (2020) Cancer associated thrombosis and mortality in patients with cancer stratified by Khorana score risk levels. Cancer Med 9(21):8062–8073

Article  PubMed  PubMed Central  Google Scholar 

Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Zöchbauer-Müller S, Preusser M, Pabinger I, Ay C (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137(12):1669–1678

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, Esposito J, Claerhout B (2023) A global federated real-world data and analytics platform for research. JAMIA Open 6(2):ooad035

Article  PubMed  PubMed Central  Google Scholar 

Overvad TF, Skjøth F, Piazza G, Noble S, Ording AG, Larsen TB, Nielsen PB (2022) The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study. J Thromb Haemostasis: JTH 20(12):2921–2929

Article  CAS  Google Scholar 

Gong J, Drobni ZD, Alvi RM, Murphy SP, Sullivan RJ, Hartmann SE, Gilman HK, Lee H, Zubiri L, Raghu VK, Karp-Leaf RS, Zafar A, Zlotoff DA, Frigault MJ, Reynolds KL, Neilan TG (1990) Immune checkpoint inhibitors for cancer and venous thromboembolic events, European journal of cancer (Oxford, England: 158 (2021) 99–110

Icht O, Darzi N, Shimony S, Jacobi O, Reinhorn D, Landman Y, Mutai R, Averbuch I, Shochat T, Spectre G, Raanani P, Rotem O, Dudnik E, Peled N, Zer A, Leader A (2021) Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemostasis: JTH 19(5):1250–1258

Article  CAS  Google Scholar 

Alma S, Eloi D, Léa V, Julie C, Valérie M, Pierre G, Hilgers W, Philippe G, Christine Z, Philippe D (2022) Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Thrombolysis 54(2):287–294

Article  CAS  PubMed  Google Scholar 

He X, Wei SN, Qin WW, Geng N, Li B, Song S, Wang P (2023) Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients. Expert Rev Hematol 16(12):1135–1142

Article  CAS  PubMed  Google Scholar 

Zhang J, Xie Y, Yang L, Yang M, Xu R, Liu D (2024) Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors. BMC Pulm Med 24(1):507

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bosch FTM, Mulder FI, Kamphuisen PW, Middeldorp S, Bossuyt PM, Büller HR, van Es N (2020) Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. Blood Adv 4(20):5215–5225

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee LH, Gallus A, Jindal R, Wang C, Wu CC (2017) Incidence of venous thromboembolism in Asian populations: A systematic review. Thromb Haemost 117(12):2243–2260

Article  PubMed  Google Scholar